Key result
Compound 1e showed anti-EV 71 activity with IC50 values of 5.7-12 μM and lower cytotoxicity to Vero cells (TC50 = 620 μM) compared to pirodavir (TC50 = 31 μM).
Compound 1e is a promising lead compound for the development of anti-EV 71 drugs due to its antiviral activity and low cytotoxicity.
Answers are grounded in this paper and cite their sources.
No immediate clinical application; leaves open further preclinical development of these derivatives as EV71 antivirals.
A series of novel N-phenylbenzamide derivatives were synthesized and their anti-EV 71 activities were assayed in vitro. Among the compounds tested, 3-amino-N-(4-bromophenyl)-4-methoxybenzamide (1e) was active against the EV 71 strains tested at low micromolar concentrations, with IC50 values ranging from 5.7 ± 0.8-12 ± 1.2 μM, and its cytotoxicity to Vero cells (TC50 = 620 ± 0.0 μM) was far lower than that of pirodavir (TC50 = 31 ± 2.2 μM). Based on these results, compound 1e is a promising lead compound for the development of anti-EV 71 drugs.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2013) studied Enterovirus 71 infection. 3-amino-N-(4-bromophenyl)-4-methoxybenzamide (1e) vs. pirodavir was evaluated on anti-EV 71 activity (IC50) and cytotoxicity (TC50). Compound 1e showed anti-EV 71 activity with IC50 values of 5.7-12 μM and lower cytotoxicity to Vero cells (TC50 = 620 μM) compared to pirodavir (TC50 = 31 μM).
Synapse has enriched 10 related papers. Consider them for comparative context: